Featured DVD: New Drug Update 28

REGISTER NOW

New Drug Update

The New Drug Update is in its 28th year and is the most comprehensive, evidenced-based discussion of new drugs. This original course is only available through University Learning Systems. Turn your next trip into your own personalized CE/CME getaway with New Drug Update 28. Anytime! Anywhere!

This program in its entirety provides 10 hours (1.0 CEU) of ACPE CPE home study credit, AMA Category 2 CME, and CNE pharmacology credit.

Faculty

C. Wayne Weart, Pharm.D., FASHP, FAPhA, BCPS
Professor Emeritus of Family Medicine, Department of Family Medicine
Medical University of South Carolina, Professor Emeritus of Clinical Pharmacy and Outcome Sciences, South Carolina College of Pharmacy, MUSC Campus, Charleston, South Carolina.

Testimonial

“Dr Weart’s knowledge is amazing. He is able to answer any question using evidence from studies. His ability to separate facts from opinions and hype from studies is very helpful.”
– Past attendee of Dr. Weart’s seminars

Course Fee

  • General Course Fee: $99
  • Shipping outside the continental US is an additional $50

Recording

This program was originally presented and recorded June 7-8, 2017 at a CE / CME conference for health professionals in Las Vegas.

Course Objectives

At the conclusion of this session, the participant should be able to:

  1. Identify recent FDA drug communications, including but not limited to, labeling changes, warnings, new indications, new dosage forms , and MedWatch alerts;
  2. Discuss the new drugs with respect to their pharmacology, pharmacokinetics, approved and unapproved indications;
  3. Describe their adverse effects and drug interactions that may affect patient compliance;
  4. Compare efficacy, dosage and cost to existing agent;
  5. Discuss the patient oriented outcomes or evidence that may or may not exist for each of the new medications and when they may or may not be appropriate to recommend for selected patients.

Course Contents

Part 1:  Zoster , Influenza, Meningitis, HPV, Tdap/ Pertussis, Hepatitis B, Valsartan/Sacubitril – Entresto, Drugs Commonly Used for HFrEF, Digoxin, Ivabradine – Corlanor, Metformin, SGLT-2 inhibitors, liraglutide, Xultophy (IDegLira), Lixisenatide – Adlyxin by Sanofi, Lixisenatide, Byduron, Soliqua™ 100/33 (insulin glargine & lixisenatide injection), Semaglutide a once a week GLP-1 analog, Toujeo – Insulin glargine U-300, Insulin Glargine – Basaglar, Insulin Glargine U100 – MK1293,   Insulin Glargine U100 by Mylan/Bioepis, Insulin Degludec- Tresiba, Insulin Degludec/Aspart 70/30 – Ryzodeg, Insulin Lispro – Humalog U-200, Humulin R U-500 KwikPen, DPP-4 Inhibitors, Hypertension.

Part 2:  Ezetimibe 10 mg , Ezetimibe/Simvastatin, PCSK9 mAb, Alirocumab-Praluent, Evolocumab – Repatha, Bococizumab Investigational PCSK-9 Inhibitor by Pfizer, Extended Release Aspirin – Durlaza, Aspirin/omeprazole 81mg-40mg and 325mg-40mg tablets – Yosprala, Auvi-Q Auto-injector, Epi-Pen, Adrenaclick Brand, Fluticasone furoate /Vilanterol inhalation powder –Breo Ellipta, ICS/LABA Combination , Umeclidinium and Vilanterol – Anoro Ellipta, Umeclidinium – Incruse Ellipta Inhaler, Tiotropium – Spiriva Respimat, Glycopyrrolate – Seebri Neohaler by Novartis, Glycopyrrolate and Indacaterol – Utibron Neohaler, Combination of Glycopyrrolate and Formoterol – Bevespi Aerosphere, Combination of Tiotropium and Olodaterol – Stiolto Respimat, ICS/LABA/LAMA Combinations, Arnuity Ellipta (fluticasone furoate inhalation powder), Albuterol sulfate inhalation powder – ProAir Respiclick, Fluticasone propionate /Salmeterol inhalation powder AirDuo RespiClick, Generic Advair (fluticasone/salmeterol), Fluticasone propionate – ArmonAir RespiClick, Tiotropium – Spiriva Respimat 1.25 mcg/inhalation for Asthma, House Dust Mite Allergen Extract – Odactra ,  Nitroglycerin sublingual powder –   GoNitro, Narcan Nasal Spray, EVZIO (Naloxone) Auto-Injector, Valbenazine – Ingrezza, Related Medication: Tetrabenazine-Zenazine, Deutetrabenazine – Austedo, Safinamide – Xadago, Rasagiline , Entacapone, Pimavanserin – Nuplazid, Fluconazole, flouroquinolones.

Accreditation/ Target Audience

Physicians: This course provides ten (10) hours of AMA Category 2 credit.

American Osteopathic Association (AOA): American Osteopathic Association (AOA): This course provides ten (10) hours of AMA Category 2 credit.

Canadian Physicians:  Members of the College of Family Physicians of Canada CFPC : This course provides ten (10) hours of AMA Category 2 credit.

Physician Assistants:  American Academy of Physician Assistants (AAPA): This course provides ten (10) hours of AMA Category 2 credit.

Nurse Practitioners: American Nurses Credentialing Center (ANCC):  Continuing education hours approved by AAFP and by ACPE meet the ANCC-accredited CNE criteria. This course provides Category 1 Continuing Education Hours for certification renewal. The same hours submitted to renew certification may be submitted to a State Board of Nursing for re-licensure.

National Certification Corporation (NCC): Recognizes any Nursing, Medical, Health Care or Other For Profit or Not for Profit Education Provider. Please contact NCC regarding approval.

American Academy of Nurse Practitioners Certification Program (AANPCP): National Certification Program for Nurse Practitioners accepts AAFP Prescribed credit and ACPE credit.

Nurses: University Learning Systems is approved by the California Board of Registered Nursing, Provider Number CEP 11409.

Pharmacists/Pharmacist Technicians: University Learning Systems (ULS), is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a Provider of continuing pharmacy education. All ULS courses carry ACPE credit with the designation for pharmacists (P) or pharmacist technicians (T). DVD courses are recognized as home study courses by ACPE

Part 1: ACPE UAN 0741-0000-17-016-H01-P,  0741-0000-17-016-H01-T, Activity: Knowledge; 5 Contact Hours until June 7, 2020. Part 2: ACPE UAN 0741-0000-17-017-H01-P,  0741-0000-17-017-H01-T, Activity: Knowledge; 5 Contact Hours until June 8, 2020.   

Credit

This program in its entirety provides 10 hours (1.0 CEU) of AAFP Prescribed Credit , AMA category 2 CME, CNE, home study CPE pharmacology credit. Part 1 and Part 2 must be taken together. No partial credit is awarded. This program was originally presented and recorded June 7-8, 2017 at a continuing education seminar for health professionals in Las Vegas.

Requirements for Credit

Credit is dependent on obtaining a score of 70% on self assessment tests or quizzes and submitting the completed the course evaluation. Upon receipt of your test answers and evaluation, University Learning Systems will email test feedback and your statement of credit (physicians, physician assistants, nurses, nurse practitioners, and non-US health professionals), report credit to CPE Monitor (pharmacists) and report credit to other organizations that you specify such as CE Broker. Please provide all necessary reporting information at the time of registration.

Pharmacists: Please ensure that we have your NABP e-profile ID  and date of birth on file. Credit will be reported electronically to CPE Monitor. Paper statements of credit can be downloaded from CPE Monitor. Please inform University Learning Systems if you require that credit be reported to CE Broker (University Learning Systems CE Broker Provider # 50-11357) and provide all necessary reporting information when you register for this course.

Contact University Learning Systems

University Learning Systems
P.O. Box 35
East Amherst, NY 14051
Phone: 800-940-5860
Email: info@universitylearning.com
Fax: 716-529-0550

medical-cme-conference-pharmacy-ce-seminar-pharmacist-ce-new-drug-update